1 / 5

Michael Yassa, MD, FRCPC Radiation Oncologist, Hôpital Maisonneuve-Rosemont

Late consequential effects of hypofractionated radiotherapy in prostate cancer: impact of acute toxicity on toxicity at 4 years and 8 years. Michael Yassa, MD, FRCPC Radiation Oncologist, Hôpital Maisonneuve-Rosemont Assistant Professor, University of Montreal myassa.hmr@ssss.gouv.qc.ca

tanner
Télécharger la présentation

Michael Yassa, MD, FRCPC Radiation Oncologist, Hôpital Maisonneuve-Rosemont

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Late consequential effects of hypofractionated radiotherapy in prostate cancer: impact of acute toxicity on toxicity at 4 years and 8 years. Michael Yassa, MD, FRCPC Radiation Oncologist, Hôpital Maisonneuve-Rosemont Assistant Professor, University of Montreal myassa.hmr@ssss.gouv.qc.ca P. Vavassis (I), B. Fortin (I), M.A. Fortin (II), C. Lambert (III), T.V. Nguyen (III), and J.P. Bahary (III) I) Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont II) Department of Radiation Oncology, Cité de la Santé de Laval III) Department of Radiation Oncology, CHUM – Hôpital Notre-Dame

  2. Key Points • OBJECTIVE: Evaluate late consequential effects in patients who underwent hypofractionated radiotherapy • 42 patients with intermediate-risk prostate cancer • RT: 57 Gy in 19 fractions (3 Gy per fraction) • Patients followed prospectively (median follow-up 8.4 yrs) • Toxicity recorded according to the NCI-CTC version 2 • Analysis of toxicity in acute phase, at 4 yrs and 8 yrs

  3. Results • Previously reported acute grade 3 GU and GI toxicity were 5% and 0%, respectively. • Of the patients with acute grade 3 GU toxicity, none had toxicity at 4 years and only one patient had grade 2 GU toxicity at 8 years. • No difference in chronic toxicity in patients with acute grade 0-1 toxicity (23% at 8 years) vs. those with acute grade 2-3 toxicity (20% at 8 years).

  4. Results • At 8 years, 79% of patients were asymptomatic

  5. Conclusion • No significant acute or chronic toxicity with this regimen (57Gy in 19 fractions). • No late consequential side effects with hypofractionation in prostate cancer using 3Gy per fractions.

More Related